Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2018-12-14 | Dr. Rosenblatt currently serves as Chief Medical Officer of Flagship Pioneering... The Board has concluded that Dr. Rosenblatt should continue to serve as a director of the Corporation because of his leadership and executive experience... Director Compensation Table shows total compensation of $36,740. |
| 2019-12-17 | Dr. Rosenblatt currently serves as Chief Medical Officer of Flagship Pioneering... The Board has concluded that Dr. Rosenblatt should continue to serve as a director of the Company because of his leadership and executive experience in the biotechnology industry... The following table sets forth the total compensation paid or accrued during the fiscal year ended September 30, 2019 to each of our non-employee directors... Michael Rosenblatt $212,522. |
| 2020-12-15 | Michael Rosenblatt Nominee Information Dr. Rosenblatt currently serves as Chief Medical Officer of Flagship Pioneering, a Cambridge, Massachusetts-based firm that originates new biotech companies. Prior to Flagship Pioneering, from 2009 through 2016, he was Executive Vice President and Chief Medical Officer of Merck & Co., Inc., and prior to that he held various academic positions, including as Dean of Tufts University School of Medicine and the Robert Ebert Professor of Molecular Medicine and the George R. Minot Professor at Harvard Medical School. Since 2015 Dr. Rosenblatt has been on the board of Rubius Therapeutics, a publicly traded company using advanced cellular approaches that harness properties of red blood cells to generate novel therapies. He has been a director of the following privately owned companies since 2016: Flagship Pioneering’s Cobalt Biomedicine, Cygnal Therapeutics, and Ohana Biosciences, and Ferring’s USA subsidiary. Dr. Rosenblatt is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of Massachusetts General, Brigham and Women’s, and Boston Children’s hospitals. Qualifications The Board has concluded that Dr. Rosenblatt should continue to serve as a director of the Company because of his leadership and executive experience in the biotechnology industry, including as the chief medical officer of a major pharmaceutical company and at a substantial life sciences venture capital firm, his board-level experience as a founding scientist, scientific advisory board member, or director of more than a dozen biopharmaceutical companies, his academic leadership experience as a dean and professor at prestigious medical schools, and his extensive expertise in drug discovery and medical research. Committees of the Board Michael Rosenblatt serves on the Human Resources and Compensation Committee. Director Compensation Table Michael Rosenblatt received total compensation of $217,534 in fiscal 2020. |
| 2021-12-15 | Dr. Rosenblatt has been a director since September 2018. The Human Resources and Compensation Committee is currently comprised of Ms. Zane (Chair), Dr. Rosenblatt and Ms. Davis. The Finance Committee is comprised of Ms. Davis (Chair), Professor Palepu and Drs. Rosenblatt and Wrighton. |
Data sourced from SEC filings. Last updated: 2026-02-03